Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
O.SterneJ
27, 2024 /CNW/ - Novo Nordisk announced today that Wegovy (semaglutide injection) is now approved to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI equal to or greater than 27 kg/m 2
Longer-term studies are still needed to evaluate sustained efficacy and safety beyond 72 weeks
They can improve blood pressure, lipid profiles, and endothelial function, which are crucial for a healthy cardiovascular system and reducing cardiovascular risk factors
US$ 26.48
US$ 28.07
US$ 21.22
US$ 20.68
US$ 29.38
US$ 25.99
US$ 21.33
US$ 28.44
US$ 22.01
